Adoptive immunotherapy in the treatment of malignant disease.
Klein
H G
HG
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institute of Health, Bethesda, Maryland.
Leitman
S F
SF
D000818:Animals; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000637:transplantation; D008218:Lymphocytosis / Q000139:chemically induced; D051379:Mice; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000637:transplantation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D012074:Remission Induction; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
D007376:Interleukin-2; D011994:Recombinant Proteins